Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 2015  Peter Walter wurde als Gewinner ... seine bahnbrechende Arbeit ausgewählt, die sich damit ... sowie für die Entschlüsselung der Komponenten eines ... nutzen, der mit der Ansammlung von deformierten ... Biochemie an der University of California, San ...
(Date:3/27/2015)... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... platform company serving the global pharmaceutical, biotechnology, and ... New Drug (IND) application for WuXi MedImmune,s novel ... accepted for review by the China Food and ... 2012, MedImmune, the global biologics research and development ...
(Date:3/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... with certain matters, including the appointment of auditors, its ... 26, 2015 (the "Meeting") was adjourned, as previously disclosed ... 11:00 a.m. ( Toronto time). The ... that previous disclosed. The Meeting will reconvene at the ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
Breaking Biology Technology:Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 2Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 3Deutschstämmiger Zellbiologe Peter Walter gewinnt den Vilcek Prize in Biomedical Science 2015 4Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 2Investigational New Drug Application for WuXi MedImmune's Monoclonal Antibody Accepted for Review by CFDA 3SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... that a new market research report is available in ... Technologies and Global Markets http://www.reportlinker.com/p0298002/Cancer-Profiling-and-Pathways-Technologies-and-Global-Markets.html ... Cancer Profiling Technologies at about $15 billion in 2009. ... 2010 and $47 billion by 2015, at a compound ...
... BURLINGTON, Mass., Sept. 23 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that growth ... by chronic myelogenous leukemia (CML) therapies (Novartis,s Gleevec ... lymphocytic leukemia (CLL) therapies (Biogen Idec/Roche,s Rituxan and ...
... samples generated during clinical research is rapidly increasing as ... traditional medicine to molecular-based therapeutics. The growing use of ... an increasing emphasis on the value of sample integrity ... collect, store and distribute clinical trial samples. ...
Cached Biology Technology:Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 2Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 3Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 4Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 5Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 6Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 7Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 8Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 9Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 10Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 11Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 12Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 13Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 14Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 15Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 16Reportlinker Adds Cancer Profiling and Pathways: Technologies and Global Markets 17Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 2BioStorage Technologies Brings Together Industry Leaders for Global Sample Management Benchmarking Symposium 3
(Date:3/16/2015)... , March 16, 2015 ... Systems GmbH will present groundbreaking innovations in biometric ... Hanover, Germany .      (Photo: ... latest biometric innovation is well at the forefront: ... generation e-gate made in Germany ...
(Date:3/11/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ... Control Market by Product, Application & By Geography - ... their offering. , This report predicts that ... billion by 2020, with an estimated CAGR of 10.6%. ... products types such as contact cards & readers, contactless ...
(Date:3/10/2015)... , March 10, 2015  NXT-ID, Inc. (NASDAQ: ... the "Company"), a biometric authentication company focused on ... Wocket™ smart wallet has been named the "Number ... Modern. Rethink Modern ( http://www.rethinkmodern.com/ ) ... for your home and lifestyle that have a unique ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 2NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 3NXT-ID's Wocket Smart Wallet Named Number One Best Tech Gift for 2015 by Rethink Modern 4
... climate change will reach a tipping point in less ... health of the planet,s coral reef ecosystems according to ... Released by the Global Coral Reef Monitoring Network and ... partnerships, "Status of Coral Reefs of the World: 2008" ...
... by a Michigan State University chemist could eventually lead ... drugs that are key to treating a number of ... in drug manufacture and research often are made within ... That protein tends to collect into what scientists call ...
... study published in the current issue of CELL ... - fat cells - could become a source for ... , According to the study,s lead researcher, Dr. Yuki ... University School of Medicine, Kawasaki, Japan, adipose-derived stem/stromal cells ...
Cached Biology News:Time running out on coral reefs as climate change becomes increasing threat 2Time running out on coral reefs as climate change becomes increasing threat 3Transplanted fat cells restore function after spinal cord injury 2
Request Info...
... The Fujifilm Life Science FLA-7000 excels ... silver-stained, CBB-stained gel documentation. It features four ... R710, and a filter for Imaging Plates) ... offers a customizable choice of four kinds ...
... Labeling Kit generates labeled cDNA for use ... is made via a reverse transcription from ... Unlike other methods, there are no unnatural ... reaction. This unmodified cDNA is then labeled ...
... enables fully automated hybridization of microarrays on ... been designed to offer researchers improved reproducibility, ... perform a wide range of applications. ... 485C; denaturations of up to 99C. The ...
Biology Products: